These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 10802401)

  • 1. Application and maintenance habits do make a difference in adhesion of Alora transdermal systems.
    Gomez-Panzani E; Williams MB; Kuznicki JT; Myers WR; Zoller SA; Bixler CA; Winkler LC
    Maturitas; 2000 Apr; 35(1):57-64. PubMed ID: 10802401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy on climacteric symptoms of a new estradiol transdermal patch with active matrix in comparison with a reference reservoir patch. Two long-term randomized multicenter parallel-group studies.
    Rovati LC; Schmid K; Giacovelli G; Bonn M; Setnikar I; Wolff F; Genazzani AR
    Arzneimittelforschung; 1999 Nov; 49(11):933-43. PubMed ID: 10604047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significant differences in estradiol bioavailability from two similarly labelled estradiol matrix transdermal systems.
    Buch AB; Shen LZ; Kelly SC; Russell DA; Sahota RS; Bixler CA; Moehrke W; Powell JH
    Climacteric; 1999 Dec; 2(4):248-53. PubMed ID: 11910658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steady-state bioavailability of estradiol from two matrix transdermal delivery systems, Alora and Climara.
    Buch A; Shen L; Kelly S; Sahota R; Brezovic C; Bixler C; Powell J
    Menopause; 1998; 5(2):107-12. PubMed ID: 9689205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experience with a seven-day estradiol transdermal system for estrogen replacement therapy.
    Gordon SF
    Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 2):998-1004. PubMed ID: 7573298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved patient acceptability with a transdermal drug-in-adhesive oestradiol patch.
    Lake Y; Pinnock S
    Aust N Z J Obstet Gynaecol; 2000 Aug; 40(3):313-6. PubMed ID: 11065040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of a new 7-day transdermal estradiol patch versus placebo in hysterectomized women with postmenopausal complaints.
    von Holst T; Salbach B
    Maturitas; 2000 Feb; 34(2):143-53. PubMed ID: 10714909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of estradiol and of estrone during application of a new 7-day estradiol transdermal patch with active matrix.
    Setnikar I; Rovati LC; Vens-Cappell B; Hilgenstock C
    Arzneimittelforschung; 1998 Mar; 48(3):275-85. PubMed ID: 9553686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study to evaluate skin irritation and adhesion of Estradot and Climara in healthy postmenopausal women.
    Ibarra de Palacios P; Schmidt G; Sergejew T; Quebe-Fehling E; Lockhart L; Krinsky L
    Climacteric; 2002 Dec; 5(4):383-9. PubMed ID: 12626218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the local tolerability and adhesion of a new matrix system (Menorest) for estradiol delivery with an established transdermal membrane system (Estraderm TTS).
    Erianne JA; Winter L
    Maturitas; 1997 Mar; 26(2):95-101. PubMed ID: 9089558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative absorption and variability in absorption of estradiol from a transdermal gel and a novel matrix-type transdermal patch.
    Järvinen A; Bäckström A; Elfström C; Viitanen A
    Maturitas; 2001 Apr; 38(2):189-96. PubMed ID: 11306208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). I. Tolerability, adhesion and efficacy.
    Rozenbaum H; Birkhäuser M; De Nooyer C; Lambotte R; Pornel B; Schneider H; Studd J
    Maturitas; 1996 Nov; 25(3):161-73. PubMed ID: 8981333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women.
    Samsioe G; Dvorak V; Genazzani AR; Hamann B; Heikkinen J; Mueck AO; Suzin J; Kawakami FT; Ferreira A; Sun D; Arguinzoniz M
    Maturitas; 2007 Jun; 57(2):171-81. PubMed ID: 17317046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, safety and acceptability of a seven-day, transdermal estradiol patch for estrogen replacement therapy.
    Jarupanich T; Lamlertkittikul S; Chandeying V
    J Med Assoc Thai; 2003 Sep; 86(9):836-45. PubMed ID: 14649968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative bioavailability study of an once-a-week matrix versus a twice-a-week reservoir transdermal estradiol delivery systems in postmenopausal women.
    Baracat E; Haidar M; Castelo A; Tufik S; de Lima GR; Vieira JG; Peloso U; Casoy J
    Maturitas; 1996 Apr; 23(3):285-91. PubMed ID: 8794422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
    Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of estradiol and of estrone during repeated transdermal or oral administration of estradiol.
    Setnikar I; Rovati LC; Vens-Cappell B; Hilgenstock C
    Arzneimittelforschung; 1996 Aug; 46(8):766-73. PubMed ID: 9125276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of a seven-day, transdermal estradiol drug-delivery system: comparison with conjugated estrogens and placebo. The Transdermal Estradiol Patch Study Group.
    Gordon SF; Thompson KA; Ruoff GE; Imig JR; Lane PJ; Schwenker CE
    Int J Fertil Menopausal Stud; 1995; 40(3):126-34. PubMed ID: 7663539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estradiol and estrone plasma levels during application of three strengths of a 7-day estradiol transdermal patch.
    Setnikar I; Rovati LC; Santoro A; Guillaume M; Mignot A; Renoux A; Gualano V
    Arzneimittelforschung; 1999 Aug; 49(8):708-15. PubMed ID: 10483519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause.
    Notelovitz M; Cassel D; Hille D; Furst KW; Dain MP; VandePol C; Skarinsky D
    Am J Obstet Gynecol; 2000 Jan; 182(1 Pt 1):7-12. PubMed ID: 10649149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.